NEW YORK, Jan. 31, 2018 /PRNewswire/ --WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on ARNA, ARWR, AXON, and BIIB which can be accessed for free by signing up to www.wallstequities.com/registration. The Biotech sector started off the year strong with multiple acquisitions and partnerships, beginning to usher in the long-awaited M&A spike, according to a Seeking Alpha report. Furthermore, unlike last October, earnings season this time has opened strongly and is not hurting the building biotech momentum, added the report. Ahead of today's trading session, WallStEquities.com turns investors' attention to Arena Pharmaceuticals Inc. (NASDAQ: ARNA), Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR), Axovant Sciences Ltd (NASDAQ: AXON), and Biogen Inc. (NASDAQ: BIIB). All you have to do is sign up today for this free limited time offer by clicking the link below.
www.wallstequities.com/registration
Arena Pharmaceuticals
San Diego, California-based Arena Pharmaceuticals Inc.'s shares gained 2.38%, closing Tuesday's trading session at $37.49. The stock recorded a trading volume of 529,496 shares. The Company's shares have advanced 8.23% in the last month, 34.71% over the previous three months, and 158.55% over the past year. The stock is trading 13.90% above its 50-day moving average and 59.60% above its 200-day moving average. Additionally, shares of Arena Pharma, which focuses on developing novel small molecule drugs for various therapeutic areas in the US and Switzerland, have a Relative Strength Index (RSI) of 57.09.
On January 18th, 2018, research firm Credit Suisse resumed its 'Outperform' rating on the Company's stock, with a target price of $44 per share. Get the full research report on ARNA for free by clicking below at:
www.wallstequities.com/registration/?symbol=ARNA
Arrowhead Pharmaceuticals
On Tuesday, shares in Pasadena, California headquartered Arrowhead Pharmaceuticals Inc. recorded a trading volume of 1.34 million shares. The stock declined slightly by 0.49%, ending the day at $6.14. The Company's shares have surged 54.66% in the past month, 68.22% in the previous three months, and 250.86% over the past year. The stock is trading above its 50-day and 200-day moving averages by 44.01% and 113.31%, respectively. Furthermore, shares of Arrowhead Pharma, which develops medicines for the treatment of intractable diseases in the US, have an RSI of 68.61.
On January 05th, 2018, research firm B. Riley FBR, Inc. initiated a 'Neutral' rating on the Company's stock, with a target price of $3 per share.
On January 22nd, 2018, Arrowhead Pharma (ARWR) closed the previously announced underwritten public offering of 11,500,000 shares of its common stock, which included shares issued upon the exercise in full by the underwriters of their option to purchase 1,500,000 additional shares. The offering was priced at $5.25 per share, and ARWR received gross proceeds of approximately $60.4 million, before deducting underwriting discounts, commissions, and other offering expenses, payable by the Company. ARWR's complimentary research coverage is a few simple steps away at:
www.wallstequities.com/registration/?symbol=ARWR
Axovant Sciences
London, the UK-based Axovant Sciences Ltd's stock finished the day 3.72% lower at $2.07. A total volume of 1.85 million shares was traded, which was above their three months average volume of 1.54 million shares. The Company's shares are trading below their 50-day moving average by 52.50%. Additionally, shares of Axovant Sciences, which engages in developing and commercializing medicines for the treatment of dementia and related neurological disorders in the US and Europe, have an RSI of 23.72.
On January 08th, 2018, Axovant Sciences announced that its investigational drug intepirdine did not meet its primary efficacy endpoints in the Phase-2b HEADWAY and pilot Phase-2 Gait and Balance studies. Separately, the Company's investigational drug nelotanserin met its prespecified primary endpoint of safety in the pilot Phase-2 Visual Hallucination study.
On January 10th, 2018, research firm Chardan Capital Markets upgraded the Company's stock rating from 'Sell' to 'Neutral', with a target price of $2.50 per share. Register for your free research report on AXON at:
www.wallstequities.com/registration/?symbol=AXON
Biogen
Shares in Cambridge, Massachusetts headquartered Biogen Inc. ended yesterday's session 1.64% lower at $352.59. The stock recorded a trading volume of 1.11 million shares. The Company's shares have advanced 10.07% in the last month, 14.57% over the previous three months, and 38.66% over the past year. The stock is trading 7.31% and 17.76% above its 50-day and 200-day moving averages, respectively. Moreover, shares of Biogen, which discovers, develops, manufactures, and delivers therapies for the treatment of neurological and autoimmune diseases worldwide, have an RSI of 59.19.
On January 25th, 2018, Biogen reported its Q4 and full-year 2017 financial results. For Q4 2017, total revenues were $3.3 billion, GAAP net loss was $(297) million, and non-GAAP net income was $1.1 billion. For the full year 2017, total revenues were $12.3 billion, GAAP net income was $2.5 billion, and non-GAAP net income was $4.6 billion. Wall St. Equities' downloadable research report on BIIB available at:
www.wallstequities.com/registration/?symbol=BIIB
--
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
https://wallstequities.com/legal-disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: [email protected] Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
Advertisement
www.wallstequities.com/registration
Arena Pharmaceuticals
San Diego, California-based Arena Pharmaceuticals Inc.'s shares gained 2.38%, closing Tuesday's trading session at $37.49. The stock recorded a trading volume of 529,496 shares. The Company's shares have advanced 8.23% in the last month, 34.71% over the previous three months, and 158.55% over the past year. The stock is trading 13.90% above its 50-day moving average and 59.60% above its 200-day moving average. Additionally, shares of Arena Pharma, which focuses on developing novel small molecule drugs for various therapeutic areas in the US and Switzerland, have a Relative Strength Index (RSI) of 57.09.
Advertisement
On January 18th, 2018, research firm Credit Suisse resumed its 'Outperform' rating on the Company's stock, with a target price of $44 per share. Get the full research report on ARNA for free by clicking below at:
www.wallstequities.com/registration/?symbol=ARNA
Arrowhead Pharmaceuticals
On Tuesday, shares in Pasadena, California headquartered Arrowhead Pharmaceuticals Inc. recorded a trading volume of 1.34 million shares. The stock declined slightly by 0.49%, ending the day at $6.14. The Company's shares have surged 54.66% in the past month, 68.22% in the previous three months, and 250.86% over the past year. The stock is trading above its 50-day and 200-day moving averages by 44.01% and 113.31%, respectively. Furthermore, shares of Arrowhead Pharma, which develops medicines for the treatment of intractable diseases in the US, have an RSI of 68.61.
On January 05th, 2018, research firm B. Riley FBR, Inc. initiated a 'Neutral' rating on the Company's stock, with a target price of $3 per share.
On January 22nd, 2018, Arrowhead Pharma (ARWR) closed the previously announced underwritten public offering of 11,500,000 shares of its common stock, which included shares issued upon the exercise in full by the underwriters of their option to purchase 1,500,000 additional shares. The offering was priced at $5.25 per share, and ARWR received gross proceeds of approximately $60.4 million, before deducting underwriting discounts, commissions, and other offering expenses, payable by the Company. ARWR's complimentary research coverage is a few simple steps away at:
www.wallstequities.com/registration/?symbol=ARWR
Axovant Sciences
London, the UK-based Axovant Sciences Ltd's stock finished the day 3.72% lower at $2.07. A total volume of 1.85 million shares was traded, which was above their three months average volume of 1.54 million shares. The Company's shares are trading below their 50-day moving average by 52.50%. Additionally, shares of Axovant Sciences, which engages in developing and commercializing medicines for the treatment of dementia and related neurological disorders in the US and Europe, have an RSI of 23.72.
On January 08th, 2018, Axovant Sciences announced that its investigational drug intepirdine did not meet its primary efficacy endpoints in the Phase-2b HEADWAY and pilot Phase-2 Gait and Balance studies. Separately, the Company's investigational drug nelotanserin met its prespecified primary endpoint of safety in the pilot Phase-2 Visual Hallucination study.
On January 10th, 2018, research firm Chardan Capital Markets upgraded the Company's stock rating from 'Sell' to 'Neutral', with a target price of $2.50 per share. Register for your free research report on AXON at:
www.wallstequities.com/registration/?symbol=AXON
Biogen
Shares in Cambridge, Massachusetts headquartered Biogen Inc. ended yesterday's session 1.64% lower at $352.59. The stock recorded a trading volume of 1.11 million shares. The Company's shares have advanced 10.07% in the last month, 14.57% over the previous three months, and 38.66% over the past year. The stock is trading 7.31% and 17.76% above its 50-day and 200-day moving averages, respectively. Moreover, shares of Biogen, which discovers, develops, manufactures, and delivers therapies for the treatment of neurological and autoimmune diseases worldwide, have an RSI of 59.19.
On January 25th, 2018, Biogen reported its Q4 and full-year 2017 financial results. For Q4 2017, total revenues were $3.3 billion, GAAP net loss was $(297) million, and non-GAAP net income was $1.1 billion. For the full year 2017, total revenues were $12.3 billion, GAAP net income was $2.5 billion, and non-GAAP net income was $4.6 billion. Wall St. Equities' downloadable research report on BIIB available at:
www.wallstequities.com/registration/?symbol=BIIB
--
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
https://wallstequities.com/legal-disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: [email protected] Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/this-mornings-technical-outlook-on-biotech-stocks----arena-pharma-arrowhead-pharma-axovant-sciences-and-biogen-300590941.html
SOURCE Wall St. Equities
